pembrolizumab
Showing 1 - 25 of 747
Thyroid Trial in Houston (Pembrolizumab)
Recruiting
- Thyroid
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Biliary Tract Cancer Trial in Goyang-si, Seoul (SMT-NK inj.+Pembrolizumab, Pembrolizumab)
Recruiting
- Biliary Tract Cancer
- SMT-NK inj.+Pembrolizumab
- Pembrolizumab
-
Goyang-si, Gyeonggi-do, Korea, Republic of
- +2 more
Jun 28, 2022
Metastatic NSCLC Trial (Pembrolizumab coformulated with hyaluronidase, Pemetrexed, Cisplatin)
Not yet recruiting
- Metastatic Non-small Cell Lung Cancer
- Pembrolizumab coformulated with hyaluronidase
- +6 more
- (no location specified)
Jan 27, 2023
Prostate Cancer Metastatic Trial (Pembrolizumab, Carboplatin, Cabazitaxel)
Not yet recruiting
- Prostate Cancer Metastatic
- Pembrolizumab
- +2 more
- (no location specified)
Sep 29, 2022
Triple Negative Breast Cancer Trial in Shanghai (Cisplatin, Nab-paclitaxel, Pembrolizumab)
Not yet recruiting
- Triple Negative Breast Cancer
- Cisplatin
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 18, 2022
Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Tazemetostat, Pembrolizumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Tazemetostat
- Pembrolizumab
-
Saint Louis, MissouriWashington University School of Medicine
May 26, 2022
NSCLC, Melanoma Trial (IMM60, Pembrolizumab)
Not yet recruiting
- Non-small Cell Lung Cancer
- Melanoma
- IMM60
- Pembrolizumab
- (no location specified)
Jan 24, 2023
Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma Trial (Pembrolizumab)
Not yet recruiting
- Muscle Invasive Bladder Carcinoma
- +2 more
- Pembrolizumab
- (no location specified)
Jun 23, 2022
Carcinoma, Ovarian Epithelial Trial in Hidaka (pembrolizumab, olaparib, bevacizumab)
Recruiting
- Carcinoma, Ovarian Epithelial
- pembrolizumab
- +5 more
-
Hidaka, Saitama, JapanSaitama Medical Uiversity International Medical Center
Apr 25, 2022
Mucosal Melanoma Trial in Wollstonecraft (Pembrolizumab, Lenvatinib)
Not yet recruiting
- Mucosal Melanoma
- Pembrolizumab
- Lenvatinib
-
Wollstonecraft, New South Wales, AustraliaMelanoma Institute Australia
Sep 15, 2022
Tumors Trial (vibostolimab, pembrolizumab, pemetrexed)
Active, not recruiting
- Neoplasms
- vibostolimab
- +6 more
- (no location specified)
Apr 22, 2022
Colorectal Cancer Trial (Pembrolizumab)
Not yet recruiting
- Colorectal Cancer
- Pembrolizumab
- (no location specified)
Apr 13, 2022
Gastric Cancer Trial in Seoul (Pembrolizumab)
Recruiting
- Gastric Cancer
- Pembrolizumab
-
Seoul, Korea, Republic ofSamsung Medical Center
Dec 23, 2021
Tumors Trial (Favezelimab, Pembrolizumab, Oxaliplatin)
Active, not recruiting
- Neoplasms
- Favezelimab
- +7 more
- (no location specified)
Apr 11, 2022
Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma Trial in Boston
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- +3 more
- Pembrolizumab
- +3 more
-
Boston, Massachusetts
- +1 more
Feb 11, 2023
Metastatic Pancreatic Ductal Adenocarcinoma Trial in Washington (BXCL701, Pembrolizumab)
Not yet recruiting
- Metastatic Pancreatic Ductal Adenocarcinoma
- BXCL701
- Pembrolizumab
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Jan 23, 2023
NSCLC Trial (Pembrolizumab, Docetaxel)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Pembrolizumab
- Docetaxel
- (no location specified)
Aug 18, 2022
Ovarian Carcinosarcoma, Uterine Carcinosarcoma Trial (Eribulin Mesylate, Pembrolizumab)
Not yet recruiting
- Ovarian Carcinosarcoma
- Uterine Carcinosarcoma
- Eribulin Mesylate
- Pembrolizumab
- (no location specified)
Jan 31, 2023
Locally Advanced Colorectal Cancer Trial (Capecitabine, Oxaliplatin, Bevacizumab)
Not yet recruiting
- Locally Advanced Colorectal Cancer
- Capecitabine
- +3 more
- (no location specified)
Oct 18, 2022
Classical Hodgkin Lymphoma Trial in Charlottesville (Pembrolizumab, Doxorubicin, Vinblastine)
Recruiting
- Classical Hodgkin Lymphoma
- Pembrolizumab
- +4 more
-
Charlottesville, VirginiaUniversity of Virginia
Jul 27, 2022
Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)
Recruiting
- Ovarian Clear Cell Carcinoma
- Gynecologic Cancer
- Lenvatinib
- Pembrolizumab
-
Boston, MassachusettsDana Farber Cancer Institute
Aug 16, 2022